Why and how to quantify minimal residual disease in acute lymphoblastic leukemia?
about
EuroFlow antibody panels for standardized n-dimensional flow cytometric immunophenotyping of normal, reactive and malignant leukocytesMolecular detection of B-cell neoplasms by specific DNA methylation biomarkersCytotoxic effect of trans-cinnamaldehyde on human leukemia K562 cells.Clinical features and prognostic implications of TCF3-PBX1 and ETV6-RUNX1 in adult acute lymphoblastic leukemiaRelationship between minimal residual disease measured by multiparametric flow cytometry prior to allogeneic hematopoietic stem cell transplantation and outcome in children with acute lymphoblastic leukemia.MLL-rearranged B lymphoblastic leukemias selectively express the immunoregulatory carbohydrate-binding protein galectin-1.T-cell acute lymphoblastic leukemia in adults: clinical features, immunophenotype, cytogenetics, and outcome from the large randomized prospective trial (UKALL XII/ECOG 2993)Allogeneic hematopoietic cell transplantation with full-intensity conditioning for adult acute lymphoblastic leukemia: results from a single center, 1998-2006A novel approach for determining cancer genomic breakpoints in the presence of normal DNAPersistence of cytogenetic abnormalities at complete remission after induction in patients with acute myeloid leukemia: prognostic significance and the potential role of allogeneic stem-cell transplantationA sensitive array-based assay for identifying multiple TMPRSS2:ERG fusion gene variants.A simplified minimal residual disease polymerase chain reaction method at early treatment points can stratify children with acute lymphoblastic leukemia into good and poor outcome groupsEstablishment and validation of a standard protocol for the detection of minimal residual disease in B lineage childhood acute lymphoblastic leukemia by flow cytometry in a multi-center settingMalleable immunoglobulin genes and hematopathology - the good, the bad, and the ugly: a paper from the 2007 William Beaumont hospital symposium on molecular pathologyLong-term efficacy and safety of bosutinib in patients with advanced leukemia following resistance/intolerance to imatinib and other tyrosine kinase inhibitors.Flow minimal residual disease monitoring of candidate leukemic stem cells defined by the immunophenotype, CD34+CD38lowCD19+ in B-lineage childhood acute lymphoblastic leukemia.Qualitative polymerase chain reaction versus quantitative polymerase chain reaction for the detection of minimal residual disease in children with acute lymphoblastic leukemia.CD20 expression sub-stratifies standard-risk patients with B cell precursor acute lymphoblastic leukemia.
P2860
Q24604581-09BF89CA-3CBE-4154-A7FE-9352B3B7A995Q28394142-F221E5E0-5C33-44E2-BF48-C6EF17025616Q33557490-99915660-2033-4386-8CE1-6C5732A94262Q33632230-9ED06B15-8D3C-41DF-85E9-15E681205275Q33886177-DB9C0212-6462-47E6-8240-922A5A2589F0Q34060270-2A2866FC-196A-4A71-8035-66A2B74F500EQ34612782-1EF81514-148F-4C36-B52E-D4B9E0B49EF0Q35640788-8330FF79-3EFD-445A-9E29-5C6C3442FB16Q35741860-A4AC3A10-35D9-4B2F-862E-DFBA1FDF38FDQ36920398-1C899D6D-F638-4AB7-9512-E00168F3E9A3Q36972104-CA163DE0-D8A0-4CEA-A9BA-41D02FF3FD2AQ37207757-B06C1CA1-333E-49C5-A828-8206CF5E609DQ37207796-45593039-B2CB-4E03-810C-C704B66E4A36Q37238171-935BC9AB-46F7-411E-97D1-5E1B5A4F87F6Q37461942-B7773B11-7AF1-4AA1-BE78-BF8CF7EA95EBQ38377302-C8B7EDAA-26F8-454E-9108-DA201F10D0A0Q41893098-62751107-F668-4E71-AED0-73A76218134CQ47145213-0C575894-7523-4D40-8487-F3384C78C9ED
P2860
Why and how to quantify minimal residual disease in acute lymphoblastic leukemia?
description
2007 nî lūn-bûn
@nan
2007年の論文
@ja
2007年論文
@yue
2007年論文
@zh-hant
2007年論文
@zh-hk
2007年論文
@zh-mo
2007年論文
@zh-tw
2007年论文
@wuu
2007年论文
@zh
2007年论文
@zh-cn
name
Why and how to quantify minimal residual disease in acute lymphoblastic leukemia?
@ast
Why and how to quantify minimal residual disease in acute lymphoblastic leukemia?
@en
type
label
Why and how to quantify minimal residual disease in acute lymphoblastic leukemia?
@ast
Why and how to quantify minimal residual disease in acute lymphoblastic leukemia?
@en
prefLabel
Why and how to quantify minimal residual disease in acute lymphoblastic leukemia?
@ast
Why and how to quantify minimal residual disease in acute lymphoblastic leukemia?
@en
P356
P1433
P1476
Why and how to quantify minimal residual disease in acute lymphoblastic leukemia?
@en
P2093
Szczepański T
P2888
P304
P356
10.1038/SJ.LEU.2404603
P577
2007-02-15T00:00:00Z